



Data Sheet

 Product Name:
 R-268712

 Cat. No.:
 CS-5618

 CAS No.:
 879487-87-3

 Molecular Formula:
 C20H18FN50

Molecular Weight: 363.39

Target: TGF- β Receptor Pathway: TGF-beta/Smad

Solubility: DMSO: 125 mg/mL (343.98 mM; Need ultrasonic)

BIOLOGICAL ACTIVITY:

R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5 nM. IC50 value: 2.5 nM [1] Target: ALK5 in vitro: R-268712 is a novel and specific inhibitor of activin receptor-like kinase 5 (ALK5), a transforming growth factor β (TGF- β) type I receptor. R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5 nM, an approximately 5000-fold more selectivity for ALK5 than p38 mitogen-activated protein kinase (MAPK). R-268712 is a weak inhibitor of p38 MAP kinase (IC50: 12.1 μ M).[1] in vivo: Oral administration of R-268712 at doses of 1, 3 and 10 mg/kg also inhibited the development of renal fibrosis in a dose-dependent manner in a unilateral ureteral obstruction (UUO) model. [1]

PROTOCOL (Extracted from published papers and Only for reference)

Animal administration [1] R-268712 was suspended in 0.5% sodium carboxymethylcellulose (CMC) and orally administered to male WKY/Hos rats at doses of 0.3, 1, 3, and 10 mg/kg. Blood samples were collected from the jugular vein 0.5, 1, 2, 4, 6, and 24 h after dosing under isofluraneanesthesia. The plasma concentration of R-268712 was determined by API 4000 liquid chromatographytandem mass spectrometry (LC-MS/MS). Pharmacokinetic parameters were calculated with noncompartmental analysis by using Biobook.

References:

[1]. Terashima H, et al. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Eur J Pharmacol. 2014 Jul 5;734:60-6.

CAIndexNames:

1H-Pyrazole-1-ethanol, 4-[2-fluoro-5-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]phenyl]-

SMILES:

 ${\sf FC1} = {\sf C(C2} = {\sf CN(CCO)N} = {\sf C2)C} = {\sf C(C3} = {\sf CNN} = {\sf C3C4} = {\sf CC} = {\sf CC(C)} = {\sf N4)C} = {\sf C1}$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com